8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 3, 2008

NEOGEN CORPORATION

(Exact name of registrant as specified in its charter)

MICHIGAN	0-17988	38-2367843
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

620 Lesher Place Lansing, Michigan	48912
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code 517-372-9200

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

On January 3, 2008, Neogen Corporation issued a press release announcing results of operations for the fiscal quarter and six months ended November 30, 2007. A copy of the press release is attached as Exhibit 99.1 to this report. This Form 8-K and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not incorporated by reference into any filing of the Registrant, whether made before or after the date of this report, regardless of any general incorporation language in the filing.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

99.1 Press Release dated January 3, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEOGEN CORPORATION
	(Registrant)
Date: January 4, 2008
	/s/ Richard R. Current
	Richard R. Current
	Vice President & CFO

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

CONTACT:	Richard R. Current, Vice President and CFO
	517/372-9200

Neogen reports 34% increase in net income, 23% increase in revenues

LANSING, Mich., Jan. 3, 2008 – Neogen Corporation (Nasdaq: NEOG) announced today that its net income for the second quarter of FY 2008, which ended Nov. 30, increased 34% from the previous year’s second quarter. Adjusted for a 3-for-2 stock split, net income in the quarter rose to $0.22 per share, compared to the prior year’s $0.17. Neogen’s second quarter net income of $3,254,000 set another quarterly record for the 25-year-old company.

Year-to-date net income for the first six months of Neogen’s 2008 fiscal year increased 30% to $6,265,000 from $4,832,000 in FY 2007, or to $0.42 per share in the current year from the prior year’s $0.34. Second quarter revenues increased 23% to $27,210,000, also a quarterly record, compared to the prior year’s $22,189,000. Year-to-date revenues rose 18% during the fiscal year’s first half to $50,118,000 from FY 2007’s $42,409,000.

The second quarter was the 59th consecutive profitable quarter from operations for the company, and the 63rd quarter of the past 68 quarters to show increased revenues as compared with the previous year.

“Those who have followed Neogen closely know of our goal to achieve $100 million in annual sales this year, and I’m pleased to report that we are half way there after the first six months,” said James Herbert, Neogen’s chief executive officer and chairman. “The quarter’s revenue contributes to our record of compound annual growth of 19% for the past 15 years.”

Neogen’s ongoing efforts to control costs, improve productivity, and the results of economies of scale were evident in the second quarter. Operating income as a percentage of sales increased to 17.6% in the current quarter from the previous year’s comparable quarter of 16.7%. On a six-month basis, operating income is 18.6% of sales compared to 17.2% in the prior year.

“Looking ahead, the outlook for the rest of the fiscal year is encouraging,” said Lon Bohannon, Neogen’s president and chief operating officer. “Our Food Safety Division has strong momentum, and we have identified numerous domestic and international sales opportunities to grow future sales. New product introductions, and the successful integration of Kane Enterprise products, have helped our Animal Safety Division’s sales performance, and led to the division posting significant sales increases over the prior year.”

Neogen’s Food Safety Division led the company’s second quarter revenue increase, with sales up 24% from $11,691,000 in FY 2007 to $14,474,000 in FY 2008. Year-to-date, the Food Safety Division’s revenues were up 22% to $28,232,000 for FY 2008. The division’s growth was led by the third consecutive quarter of outstanding growth (over 40%) in sales of the Soleris™ general microbial detection system, a nearly 40% increase in sales of its Acumedia^® dehydrated culture media, and an increase in sales of dairy antibiotic testing products.

Scotland-based Neogen Europe, Ltd., experienced another strong quarter, with sales increasing 40% over FY 2007’s second quarter. The sales increase was led by sales of mycotoxin test kits, dehydrated culture media, and Neogen’s innovative AccuPoint^® ATP Sanitation Monitoring System.

Neogen’s Animal Safety Division second quarter revenues increased 21% to $12,736,000, compared to $10,498,000 in the previous fiscal year. For FY 2008’s first six months, the Animal Safety Division’s sales increased 13% over the comparable period last year to $21,886,000. While the August 2007 addition of Kane Enterprise’s animal health products contributed significantly to the division’s revenue gain, sales of existing products also experienced a solid 6% growth in the quarter.

Sales of OTC veterinary products increased 18% for the quarter. For the first half of FY 2008, diagnostic product sales have increased 11%, with sales of test kits to detect drugs of abuse in racing animals increasing 21% over the prior year. Sales of rodenticides to international markets also achieved strong growth over FY 2007’s second quarter. Sales of Neogen’s diphacinone products into Mexico, and the expansion of product registrations in new countries contributed to this success.

In December, Neogen announced that it had acquired the assets of Rivard Instruments, Inc., of Winnipeg, Canada. Rivard Instruments and Neogen’s subsidiary, Ideal Instruments, Inc., are both manufacturers of detectable veterinary hypodermic needles. The acquisition settles lengthy litigation between the two companies regarding numerous patents owned by each.

Neogen’s second quarter also saw Forbes Magazine name Neogen to its annual list of the 200 Best Small Companies in America for the sixth time in eight years. The Forbes list is based on growth in sales, earnings, and return on equity for the past five years, and the latest 12 months.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company’s Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen’s Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Company’s most recently filed Form 10-K.

NEOGEN CORPORATION UNAUDITED SUMMARIZED CONSOLIDATED OPERATING DATA

(In thousands, except for per share and percentages)

	Quarter ended Nov. 30						Six months ended Nov. 30
	2007			2006			2007			2006
Revenue
Food Safety	$	14,474		$	11,691		$	28,232		$	23,082
Animal Safety		12,736			10,498			21,886			19,327
Total revenue		27,210			22,189			50,118			42,409
Cost of sales		13,039			10,480			23,650			20,380
Gross margin		14,171			11,709			26,468			22,029
Other expenses
Sales & marketing		5,456			4,665			10,134			8,905
Administrative		2,862			2,333			5,192			4,137
Research & development		1,055			1,015			1,797			1,713
Total other expenses		9,373			8,013			17,123			14,755
Operating income		4,798			3,696			9,345			7,274
Other income/expense		306			5			470			59
Income before tax		5,104			3,701			9,815			7,333
Income tax		1,850			1,275			3,550			2,501
Net income	$	3,254		$	2,426		$	6,265		$	4,832
Net income per diluted share(1)	$	0.22		$	0.17		$	0.42		$	0.34
Other information:
Shares to calculate per share(1)		14,846			14,129			14,816			14,039
Depreciation & amortization	$	862		$	781		$	1,670		$	1,558
Interest expense		—			—			—			11
Gross margin (% of sales)		52.1	%		52.8	%		52.8	%		51.9	%
Operating income (% of sales)		17.6	%		16.7	%		18.6	%		17.2	%
Revenue increase vs. FY 2007		22.6	%					18.2	%
Net income increase vs. FY 2007		34.1	%					29.7	%

NEOGEN CORPORATION UNAUDITED SUMMARIZED CONSOLIDATED BALANCE SHEET DATA

(In thousands)

	Nov. 30 2007		May 31 2007
Assets
Current assets
Cash & cash equivalents	$	10,415	$	13,424
Accounts receivable		19,357		14,914
Inventory		23,142		19,116
Other current assets		3,710		3,644
Total current assets		56,624		51,098
Property & equipment		16,501		16,402
Goodwill & other assets		41,803		37,784
Total assets	$	114,928	$	105,284
Liabilities & Stockholders’ Equity
Current liabilities	$	10,174	$	10,038
Long-term lines of credit		—		—
Other long-term liabilities		3,080		3,301
Stockholders’ equity—shares outstanding 14,328 in Nov. & 14,020 in May(1)		101,674		91,945
Total liabilities & stockholders’ equity	$	114,928	$	105,284

⁽¹⁾ Reflects effect of Sept. 4, 2007, 3-for-2 stock split

###